Biocytogen is excited to attend and deliver oral and poster presentations at the upcoming 13th World ADC London conference, held on March 13th-16th, 2023.
Dr. W. Frank An, Senior Director of Antibody Therapeutics, will give an oral presentation entitled “Bispecific Antibody Drug Conjugates (BsADCs) Improve Anti-Tumour Efficacy in Preclinical Studies”. In the talk, Dr. An will introduce Biocytogen’s proprietary fully human antibody discovery platforms, with a focus on the RenLite-based bispecific antibody and bispecific ADC platforms, and the resultant novel assets emerging from the bsADC platform with superior anti-tumor efficacy. The presentation will take place in the “Discovery Stream” session, on Wednesday, March 15 at 1pm.
In addition, Biocytogen’s antibody Business Development & Licensing team will present 2 posters introducing Biocytogen’s independently developed bsADC assets.
Biocytogen has over 20 bsADC assets with first-in-class or best-in-class potential under development:
We look forward to discussing licensing and co-development opportunities with you!
About the speaker
W. Frank An, Ph.D., is the Senior Director of Antibody Therapeutics at Biocytogen. He obtained his Ph.D. in Cellular and Molecular Biology at Brandeis University, followed by postdoctoral fellowship in Immunology at Dana Farber Cancer Institute and Harvard Medical School. He has over twenty years’ experience working in drug discovery in both industry and academia settings.
About Biocytogen’s bispecific ADC platform
Tumor-associated antigens (TAAs) represent an important type of drug target, because they are highly expressed and specific to tumor cells. Bispecific antibody drug conjugates (bsADCs) targeting two TAAs aim to target tumor cells with improved specificity, internalization, and inhibition of tumor growth signals. Biocytogen’s bsADC discovery platform harnesses RenLite mice, which harbor a common light chain to facilitate the assembly of bispecific antibodies, along with KIH (knobs-into-holes) technology, to generate bispecific antibodies with a monoclonal antibody-like structure and good stability, which ensures the convenience and success rate of subsequent drug conjugation. Combinations of TAA-targeting antibodies generated from RenLite mice are subsequently screened in a high-throughput manner. Using this platform, the company has generated highly differentiated and innovative bsADCs.
As part of Biocytogen’s Project Integrum, bsADCs assembled from these TAA-targeting antibodies will be further evaluated by in vivo pharmacologic efficacy and in vitro analyses. The company’s large animal translational platform will further screen out products with better translational properties. At present, Biocytogen has 20+ bsADCs under development, with plans to submit IND applications for YH012 (HER2 x TROP2 bsADC) and YH013 (EGFR x MET bsADC) this year.
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab®/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
Antibody assets and platforms: BD-Licensing@biocytogen.com